GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (LSE:AVCT) » Definitions » Tax Expense

Avacta Group (LSE:AVCT) Tax Expense : £-2.37 Mil (TTM As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Avacta Group Tax Expense?

Avacta Group's tax expense for the months ended in Dec. 2023 was £-1.10 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2023 was £-2.37 Mil.


Avacta Group Tax Expense Historical Data

The historical data trend for Avacta Group's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group Tax Expense Chart

Avacta Group Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.56 -2.46 -2.82 -4.66 -2.37

Avacta Group Semi-Annual Data
Jul13 Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.62 -0.66 -4.00 -1.27 -1.10

Avacta Group Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-2.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avacta Group  (LSE:AVCT) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Avacta Group Tax Expense Related Terms

Thank you for viewing the detailed overview of Avacta Group's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Avacta Group (LSE:AVCT) Business Description

Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (LSE:AVCT) Headlines

No Headlines